Market Cap
$1.2B
OPK
OPKO HEALTH, INC.
$1.56 ▼ -0.64%
Prev close $1.57Market cap$1.2B
12-mo target$4.38 (+180.4%)
26 New Institutional Positions13 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on OPK right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Inst. Holders
50 funds
Inst. Value
$270.4M
Inst. Activity
26 buys / 13 sells
Insider Activity
$11.3K buy / $0.00 sell
Insider Net $
$11.3K
Social Sentiment
50° Neutral
SEC Reports
4
Press Releases
3
Price chart 30d -3.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 18, 2026 short_volume
Jul 27, 2026 SEC Short Volume: OPK — 55.2% short (0.6M / 1.0M)
Short: 571,061 | Exempt: 77,730 | TRF Vol: 1,035,199 | Short Ratio: 55.2% | Off-exchange volume (dar
OPKO Health reported Q2 2026 revenue of $163.5M, above the $131.2M consensus estimate, and a net loss of $0.01 per share
8-K — Impact 5/10
Jul 24, 2026 Insider
Rubin Steven D surrendered for taxes 53,266 shares
Executive VP-Administration @ $1.22 ($65.0K)
Jul 24, 2026 Insider
Jul 23, 2026 SEC Logal Adam surrendered for taxes 53,266 shares
Sr. Vice President, CFO @ $1.22 ($65.0K)
OPKO Health announced it will report Q2 2026 financial results on July 27, 2026, with a conference call and webcast. The
PRESS-RELEASE — Impact 2/10
Jun 30, 2026 Inst.
MORGAN STANLEY — ADD
1,975,027 shares ($3.0M)
Jun 30, 2026 Inst.
CITADEL ADVISORS LLC — TRIM
1,420,922 shares ($2.1M)
Jun 18, 2026 Insider
PFENNIGER RICHARD C JR was granted 60,000 shares
Director
Analyst ratings buy % -4.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Apr 29, 2026 | Barrington Research | DOWNGRADE | Market Perform | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 5 | 3 | 0 | 0 | 70% | |
| Aug 1, 2026 | 2 | 5 | 3 | 0 | 0 | 70% | |
| Jul 1, 2026 | 2 | 5 | 3 | 0 | 0 | 70% | |
| Jun 1, 2026 | 2 | 5 | 4 | 0 | 0 | 64% | |
| May 1, 2026 | 2 | 5 | 4 | 0 | 0 | 64% | |
| Apr 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Mar 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Feb 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% |
Price targets
Where 4 covering analysts think OPK trades over the next 12 months.
$4.38 +180.4% upside Strong Buy
Current$1.56 Low$3.00 Median$3.00 High$8.50 4 analysts
$3.00$8.50
Analyst rating None as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
4 SEC filing reports analyzed · 0 bullish, 0 bearish, 1 mixed, 3 neutral · avg impact 3.5/10.Plus 3 press releases.
MIXED8-K5/10
OPKO Health reported Q2 2026 revenue of $163.5M, above the $131.2M consensus estimate, and a net los
Jul 27, 2026
NEUTRALPRESS-RELEASE2/10
OPKO Health announced it will report Q2 2026 financial results on July 27, 2026, with a conference c
Jul 23, 2026
NEUTRALDEFA14A4/10
OPKO Health filed a DEFA14A supplement clarifying that its 2016 Equity Incentive Plan expired in Feb
May 15, 2026
NEUTRALPRESS-RELEASE3/10
OPKO Health announced it will report Q1 2026 earnings on April 28, 2026, after market close, followe
Apr 21, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 18, 2026
short_volume
Short Volume: OPK — 55.2% short (0.6M / 1.0M)
Short: 571,061 | Exempt: 77,730 | TRF Vol: 1,035,199 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
Sep 17, 2026
short_volume
Short Volume: OPK — 56.4% short (0.4M / 0.6M)
Short: 353,843 | Exempt: 839 | TRF Vol: 627,475 | Short Ratio: 56.4% | Off-exchange volume (dark pool + OTC)
Sep 14, 2026
short_volume
Short Volume: OPK — 59.0% short (0.6M / 1.0M)
Short: 571,243 | Exempt: 67,548 | TRF Vol: 969,000 | Short Ratio: 59.0% | Off-exchange volume (dark pool + OTC)
Sep 10, 2026
short_volume
Short Volume: OPK — 59.7% short (0.4M / 0.6M)
Short: 382,131 | Exempt: 3,365 | TRF Vol: 640,060 | Short Ratio: 59.7% | Off-exchange volume (dark pool + OTC)
Sep 8, 2026
earnings
OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference
MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) , a fully-integrated healthcare company focused on delivering next-generatio
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.07 | $-0.08–$-0.06 | — | +36.4% | 1↑ 0↓ | $0.1B | 2 |
| Next Q | $-0.07 | $-0.07–$-0.07 | -95.5% | +46.2% | 1↑ 0↓ | $0.1B | 2 |
| Current FY | $-0.22 | $-0.22–$-0.22 | — | +42.1% | 1↑ 0↓ | $0.6B | 1 |
| Next FY | $-0.28 | $-0.29–$-0.26 | -25.0% | +14.1% | 1↑ 0↓ | $0.6B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.070 | — |
| 7d ago | $-0.070 | — |
| 30d ago | $-0.110 | +0.040 |
| 60d ago | $-0.110 | +0.040 |
| 90d ago | $-0.110 | +0.040 |
Institutional ownership
Which big funds own OPK (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $270.4M total value (180,364,478 shares) as of 2026-Q2. Top holders: Rubric, BlackRock,, VANGUARD. Net buying activity: 26 institutions added/increased vs 13 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| Rubric Capital Management LP | 47,791,243 | $71.7M | 26.5% | — |
| BlackRock, Inc. | 36,978,893 | $55.5M | 20.5% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 14,968,930 | $22.5M | 8.3% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 14,934,924 | $22.4M | 8.3% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 11,581,027 | $17.4M | 6.4% | — |
| STATE STREET CORP | 10,309,070 | $15.5M | 5.7% | — |
| GOLDMAN SACHS GROUP INC | 7,035,492 | $10.6M | 3.9% | — |
| UBS Group AG | 5,006,284 | $7.5M | 2.8% | — |
| NORTHERN TRUST CORP | 3,756,163 | $5.6M | 2.1% | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 3,596,980 | $5.4M | 2.0% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 1,196,087 | 1,975,027 | +65.1% | $3.0M |
| CITADEL ADVISORS LLC | TRIM | 2,079,547 | 1,420,922 | -31.7% | $2.1M |
| BANK OF AMERICA CORP /DE/ | TRIM | 1,141,849 | 795,716 | -30.3% | $1.2M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | ADD | 391,516 | 623,561 | +59.3% | $935.3K |
| VAN ECK ASSOCIATES CORP | DOUBLED | 160,096 | 438,645 | +174.0% | $658.0K |
| WELLS FARGO & COMPANY/MN | DOUBLED | 162,609 | 354,039 | +117.7% | $531.1K |
| ROYAL BANK OF CANADA | ADD | 219,994 | 289,812 | +31.7% | $435.0K |
| Assenagon Asset Management S.A. | TRIM | 652,066 | 285,339 | -56.2% | $425.5K |
| Creative Planning | ADD | 176,985 | 246,065 | +39.0% | $369.1K |
| JANE STREET GROUP, LLC | NEAR_EXIT | 1,114,375 | 229,454 | -79.4% | $344.2K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
8 insiders, 10 transactions. Net $11.3K — $11.3K bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 24, 2026 | Rubin Steven D | Executive VP-Administration | TAX W/H | 53,266 | $1.22 | $65.0K |
| Jul 24, 2026 | Logal Adam | Sr. Vice President, CFO | TAX W/H | 53,266 | $1.22 | $65.0K |
| Jun 18, 2026 | PFENNIGER RICHARD C JR | Director | AWARD | 60,000 | — | — |
| Jun 18, 2026 | Lachman Prem A | Director | AWARD | 30,000 | — | — |
| Jun 18, 2026 | Yu Alice Lin-Tsing | Director | AWARD | 30,000 | — | — |
| Jun 18, 2026 | UPPALURI SUBBARAO V | Director | AWARD | 80,000 | — | — |
| Jun 18, 2026 | PAGANELLI JOHN A | Director | AWARD | 30,000 | — | — |
| Jun 18, 2026 | MEDEL ROGER MD | Director | AWARD | 30,000 | — | — |
| Mar 20, 2026 | PAGANELLI JOHN A | Director | BUY | 10,000 | $1.14 | $11.3K |
| Mar 18, 2026 | UPPALURI SUBBARAO V | Director | AWARD | 50,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for OPK.
Shares short
35,987,629
Settlement Sep 15, 2026
Change vs prior
+4.1%
Semi-monthly cycle
Days to cover
10.6
At avg daily volume
Of shares outstanding
≈4.8%
Estimate — not % of float
All OPK filing & press-release reports (7)
- 8-K reportJul 27, 2026
- PRESS-RELEASE reportJul 23, 2026
- PRESS-RELEASE reportJun 15, 2026
- DEFA14A reportMay 15, 2026
- PRESS-RELEASE reportApr 30, 2026
- PRESS-RELEASE reportApr 22, 2026
- PRESS-RELEASE reportApr 21, 2026